What is Biogen's expected EPS for Q2 2026?

Analysts expect Biogen (BIIB) to report consensus EPS of approximately $2.10 for Q2 2026. Estimates range from $-21.10 to $4.26.

What revenue do analysts expect for Biogen in Q2 2026?

The consensus revenue forecast for Biogen (BIIB) in Q2 2026 is approximately $2.46B. Forecasts range from $2.22B to $2.66B.

How many analysts cover Biogen?

21 analysts contribute to the Biogen (BIIB) Q2 2026 consensus estimate.

Has Biogen beaten earnings estimates recently?

Biogen beat analyst EPS estimates in 1 of the last 1 quarter. Biogen beat revenue estimates in 1 of 1. In the most recent quarter (Q1 2026), Biogen EPS beat by 16.9% and revenue beat by 8.4%.

When does Biogen report Q2 2026 earnings?

Biogen (BIIB) is expected to report Q2 2026 earnings on July 29, 2026 before market open.

BIIB Q2 2026 earnings estimate

Consensus EPS · Q2 2026

$2.10

Consensus revenue · Q2 2026

$2.5B

Analysts

Expected report

Jul 29, 2026

Before open

Upcoming earnings

Locks in 5 days 11 hours · BMO: Locks 8:00 PM ET previous day

Revenue$2.5B$2.2B – $2.7B

EPS$2.10-$21.10 – $4.26

What to watch

Analyst ratings: Upgrades trending

Make your prediction

Analyst consensus

Based on estimates from 21 analysts.

Metric	Low	Consensus	High
Revenue	$2.2B	$2.5B	$2.7B
EPS	-$21.10	$2.10	$4.26
EBITDA	$706.2M	$773M	$823.9M
EBIT	$566.7M	$620.3M	$661.1M
Net income	$404.8M	$467.6M	$533.3M

Revenue$2.5B
EPS$2.10
EBITDA$773M
EBIT$620.3M
Net income$467.6M

Historical beat/miss

Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.

Period	Rev. actual	Rev. est.	Rev. surprise	EPS actual	EPS est.	EPS surprise
Q1 2026	$2.5B	$2.3B	+8.4%	$3.57	$3.05	+16.9%

Q1 2026+8.4%+16.9%

Estimate revisions

How analyst consensus estimates have changed over the past 90 days.

Collecting data

Revision trends appear once we have collected at least two daily snapshots for this period.

Community vs analysts

See how the TickerLeague crowd's forecast stacks up against Wall Street.

Be the first to predict

No community consensus for Biogen (BIIB) Q2 2026 yet. Make a prediction to start the crowd forecast.

Make your prediction

Analyst price target

Based on price targets from 6 analysts.

Low: $157.00
Consensus: $220.83
Median: $225.00
High: $280.00
Current: $197.74
Upside: +11.7%

Upside calculated vs most recent trading price of $197.74.

Consensus across all covering analysts. See the ranking ›

$220.83+11.68%

Analyst ratings

Consensus: Buy — based on 48 analyst ratings.

Buy 30Hold 17Sell 1

24-month trend

Recent analyst actions

Date	Firm	Action	From	To
Jul 13, 2026	Truist Securities	upgrade	Hold	Buy
Jul 8, 2026	Morgan Stanley	maintain	Equal Weight	Equal Weight
Jul 7, 2026	RBC Capital	maintain	Outperform	Outperform
Jun 29, 2026	Needham	maintain	Buy	Buy
Jun 18, 2026	Morgan Stanley	maintain	Equal Weight	Equal Weight
Jun 15, 2026	Mizuho	maintain	Outperform	Outperform
Jun 8, 2026	Needham	upgrade	Hold	Buy
May 27, 2026	RBC Capital	maintain	Outperform	Outperform
May 15, 2026	Piper Sandler	maintain	Overweight	Overweight
May 1, 2026	Citigroup	maintain	Neutral	Neutral

Jul 13, 2026Truist SecuritiesBuy
Jul 8, 2026Morgan StanleyEqual Weight
Jul 7, 2026RBC CapitalOutperform
Jun 29, 2026NeedhamBuy
Jun 18, 2026Morgan StanleyEqual Weight
Jun 15, 2026MizuhoOutperform
Jun 8, 2026NeedhamBuy
May 27, 2026RBC CapitalOutperform
May 15, 2026Piper SandlerOverweight
May 1, 2026CitigroupNeutral

Frequently asked questions

Biogen (BIIB) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

BIIB Overview

Counters

Income Statement

Cash Flow

Capital Return

How this company returns cash to shareholders — buybacks, dividends, and stock splits.

Forecast & Valuation